Search results for "interval"
showing 3 items of 1703 documents
Explicit behavioral detection of visual changes develops without their implicit neurophysiological detectability
2011
Change blindness is a failure of reporting major changes across consecutive images if separated, e.g., by a brief blank interval. Successful change detection across interrupts requires focal attention to the changes. However, findings of implicit detection of visual changes during change blindness have raised the question of whether the implicit mode is necessary for development of the explicit mode. To this end, we recorded the visual mismatch negativity (vMMN) of the event-related potentials (ERPs) of the brain, an index of implicit pre-attentive visual change detection, in adult humans performing an oddball-variant of change blindness flicker task. Images of 500 ms in duration were prese…
Cost Efficiency of Hybrid Cloud Storage : Shortening Acquisition Cycle to Mitigate Volume Variation
2015
Hybrid cloud storage infrastructure, which combines cost-effective but inflexible private resources and flexible but premium-priced public cloud storage, allows organizations to operate cost-efficiently under demand volume uncertainty. The extant literature, however, offers a limited analytical insight into the effect that the variation of demand has on the cost-efficient mix of internal and external resources. This paper considers the storage capacity acquisition cycle, i.e. the interval at which the organization re-assesses and acquires additional resources, as a parameter shaping the optimal mix of resources. It introduces a model capturing the compound effect of the acquisition cycle an…
Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 mon…
2014
Summary Background In patients with COPD, exacerbations are associated with poor quality of life and may shorten survival. Prevention of exacerbations is, therefore, a key objective in COPD management. Indacaterol, a once-daily ultra-long-acting β 2 -agonist, has been shown to reduce exacerbations in various studies. This pooled analysis evaluated the effect of indacaterol on exacerbations versus placebo. Methods Six-month data were pooled from three randomized, double-blind, and placebo-controlled studies: indacaterol 300 μg versus placebo (1 year); indacaterol 150 μg and 300 μg versus placebo (6 months); and indacaterol 150 μg versus placebo (6 months). All treatments were administered on…